Betahistin-SZ, tablets 16 mg 60 pcs

Pharmacotherapeutic group:

Histamine drug.

ATC code: [N07CA01].

Pharmacodynamics:

Betahistine acts mainly on histamine H1- and H3-receptors of the inner ear and vestibular nuclei of the CNS. By means of direct agonist effect on H1-receptors of the inner ear vessels and indirectly through the effect on H3-receptors it improves microcirculation and capillary permeability, normalizes the endolymph pressure in the cochlea and labyrinth. At the same time betahistine increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of H3-receptor nuclei of the vestibular nerve. It improves conductivity in neurons of vestibular nuclei at brain stem level. Clinical manifestation of the above properties is reduction of frequency and intensity of dizziness, decrease of tinnitus, improvement of hearing in case of its decrease.

Pharmacokinetics:

Absorbed quickly, binding to plasma proteins is low. Maximum concentration in plasma after 3 hours. The elimination half-life is in 3-4 hours. It is almost completely excreted by the kidneys as a metabolite (2-peridylacetic acid) within 24 hours.

Indications

Meniere’s Disease, Cerebral Circulatory Disorders, Vertigo

• treatment and prevention of vestibular vertigo of various origins;
• syndromes including vertigo, headache, tinnitus, progressive hearing loss, nausea and vomiting;
• syndromes including vertigo, headache, tinnitus, nausea and vomiting
• syndromes including vertigo and headache, tinnitus, progressive hearing loss, nausea and vomiting;
• Meniere’s disease or syndrome.

.

Active ingredient

Betahistine

Composition

Active ingredient is betahistine dihydrochloride.

Auxiliary substances:

cellulose microcrystalline;

p> lactose (milk sugar);

citric acid;

Colloidal silicon dioxide (aerosil);

talc;

magnesium stearate;

sodium lauryl sulfate;

Starch 1500 (pregelatinized starch).

Description:

The tablets 16 mg are white or almost white, flat-cylindrical in color, with a bevel and a rib.

.